FDA.reportPublic FDA data

Application 200624

Type
ANDA
Sponsor
LUPIN LTD

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001REPAGLINIDE AND METFORMIN HYDROCHLORIDEMETFORMIN HYDROCHLORIDE; REPAGLINIDETABLET;ORAL500MG;1MGNoNo
002REPAGLINIDE AND METFORMIN HYDROCHLORIDEMETFORMIN HYDROCHLORIDE; REPAGLINIDETABLET;ORAL500MG;2MGNoNo

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A200624-001REPAGLINIDE AND METFORMIN HYDROCHLORIDEMETFORMIN HYDROCHLORIDE; REPAGLINIDE500MG;1MGTABLET / ORAL2015-07-15
A200624-002REPAGLINIDE AND METFORMIN HYDROCHLORIDEMETFORMIN HYDROCHLORIDE; REPAGLINIDE500MG;2MGTABLET / ORAL2015-07-15

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 3 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2022-10-28 04:53 UTC2022-10A200624-001REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;1MGTABLET / ORAL2015-07-15f41ea6bd6efb…
2022-10-28 04:53 UTC2022-10A200624-002REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;2MGTABLET / ORAL2015-07-15f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A200624-001REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;1MGTABLET / ORAL2015-07-15e64feba35796…
2022-09-29 23:25 UTC2022-09A200624-002REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;2MGTABLET / ORAL2015-07-15e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A200624-001REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;1MGTABLET / ORAL2015-07-15cb3db0bc1861…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A200624-002REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;2MGTABLET / ORAL2015-07-15cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A200624-001REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;1MGTABLET / ORAL2015-07-15a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A200624-002REPAGLINIDE AND METFORMIN HYDROCHLORIDE500MG;2MGTABLET / ORAL2015-07-15a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 2 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
68180-490Repaglinide and Metformin HydrochlorideRepaglinide and Metformin HydrochlorideLupin Pharmaceuticals, Inc.ANDACurrent
68180-491Repaglinide and Metformin HydrochlorideRepaglinide and Metformin HydrochlorideLupin Pharmaceuticals, Inc.ANDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
32043ORIG2015-07-16